• Return to search results
• Start new search

Investigator(s):
Wyndham H. Wilson, M.D., Ph.D. Principal Investigator Phone: 301-435-2415 wilsonw@mail.nih.gov	Gerald Marti, M.D., Ph.D. Protocol Chair Phone: 301-827-0453
Referral Contact(s):
Therese White, R.N., M.S.N. Research Nurse Phone: 301-402-5886 whiteth@mail.nih.gov	Nicole Grant, R.N. Research Nurse Phone: 301-594-2947 grantn@mail.nih.gov

---

Primary Eligibility:

• Open to all stages of CLL
• Age 18 and older
• No medical condition that requires chronic use of corticosteroid
• No active autoimmune hemolytic anemia or immune thrombocytopenia

---

Treatment Plan:

• Patients receive standard care with either "watch and wait" or fludarabine and rituximab treatment, as appropriate
• Patients on "watch and wait" are seen every 3-6 months
• Cycle 1 fludarabine and rituximab administered at NIH Clinical Center; referring oncologist may administer subsequent cycles
• Patients requiring treatment receive up to 6 cycles of fludarabine and rituximab. Cycles are every 28 days in length
• CLL cells are periodically collected for cDNA microarray analysis

---

Additional Information:

• This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
• There is no charge for medical care received at NIH Clinical Center.
• FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, treatment plan.
• PDQ (Physicians Data Query) - provides additional details about this study for health care providers.

Reviewed: 6/19/08
Updated: 9/7/06